Similarities Between the Binding Sites of Monoamine Oxidase (MAO) from Different Species — Is Zebrafish a Useful Model for the Discovery of Novel MAO Inhibitors? by Fierro, Angelica et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 16
Similarities Between the Binding Sites
of Monoamine Oxidase (MAO) from
Different Species — Is Zebrafish
a Useful Model for the Discovery
of Novel MAO Inhibitors?
Angelica Fierro, Alejandro Montecinos,
Cristobal Gómez-Molina, Gabriel Núñez,
Milagros Aldeco, Dale E. Edmondson,
Marcelo Vilches-Herrera, Susan Lühr,
Patricio Iturriaga-Vásquez and Miguel Reyes-Parada
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/35874
1. Introduction
Zebrafish (Danio rerio) is an animal model that is attracting increasing interest in pharmacol‐
ogy and toxicology. The relatively ease with which large numbers of individuals can be ob‐
tained and their inexpensive maintenance makes zebrafish a particularly suitable tool for
drug discovery. Thus, in recent years diverse compounds have been assayed both in larval
and adult specimens and changes of behavioral patterns, for instance, have been related to
anxiolytic, addictive or cognitive effects. In this context, the molecular characterization of
drug targets in zebrafish, comparing them to their mammalian counterparts, arises as a sub‐
ject of paramount importance.
Monoamine oxidase (MAO) is the main catabolic enzyme of monoamine neurotransmitters
and the primary target of several clinically relevant antidepressant and antiparkinsonian
drugs. In mammals, it exists in two isoforms termed MAO-A and MAO-B, which share a
number of structural and mechanistic features, but differ in genetic origin, tissue localization
and inhibitor selectivity. High-resolution structures of MAOs from rat and human have
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been reported during the last decade, allowing detailed comparison of their overall struc‐
tures and respective active sites. On the other hand, a few studies have shown that zebrafish
contains a single MAO gene and that enzyme activity is due to a single form (zMAO) which
resembles, but is distinct from, both mammalian MAO-A and MAO-B. No three-dimension‐
al structural data exist thus far for zMAO. Sequence comparison of the putative substrate
binding site of zMAO with those of human MAO isoforms suggests that the fish enzyme re‐
sembles mammalian MAO-A more than MAO-B. Nevertheless, biochemical studies have
shown that zMAO exhibits such unique behavior toward MAO-A and -B substrates and in‐
hibitors, that the results of studies using zebrafish MAO function, either as a disease model
or for drug screening, should be considered with caution.
Functional and evolutionary relationships between proteins can be reliably inferred by com‐
parison of their sequences, structures or binding sites. From a drug-discovery perspective,
the study of binding site similarities (and differences) can be particularly insightful since it
aids the design of selective or non-selective ligands and the detection of off-targets. In addi‐
tion, knowledge of ligand-binding site similarity could increase our understanding of diver‐
gent and convergent evolution and the origin of proteins, even in those cases where no
obvious sequence or structural similarity exists. In recent years, a number of algorithms
have been developed for the identification and comparison of ligand-binding sites. Even
though each method has its own merits and limitations, the performance of these computa‐
tional tools is continuously improving. Advances in this field, associated with the increasing
availability of structural data and reliable homology models of thousands to millions of pro‐
tein molecules, provide an unprecedented framework to investigate the mechanisms under‐
lying the molecular interactions between these proteins and their ligands, as well as to
evaluate the similarities between the binding sites of related and unrelated proteins
On the basis of the foregoing, the first section of this chapter provides an overview on: a) the
relevance of zebrafish as an animal model of increasing interest in pharmacology; b) the im‐
pact that MAO crystal structures and molecular simulation approaches have had on the de‐
velopment of novel MAO inhibitors, as well as comparative structural and functional
information about zMAO and its mammalian counterparts; c) recent developments in com‐
putational methods to evaluate similarities between ligand-binding sites, emphasizing their
usefulness for the rational design of multitarget (promiscuous) drugs.
The second part of the chapter describes unpublished results regarding a further characteri‐
zation of zMAO activity and its comparison with MAOs from mammals. Specific topics in
this section include: a) the construction of homology models of zMAO, built using human
MAO-A and -B crystal structures as templates; b) a three-dimensional analysis of the bind‐
ing site similarities between MAOs from different species using a statistical algorithm; c) a
functional evaluation of zMAO activity in the presence of a small series of reversible and se‐
lective MAO-A and -B inhibitors.
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2. Zebrafish as a model in pharmacology, monoamine oxidase and
computational methods to evaluate binding site similarities: An overview
2.1. Zebrafish as an animal model in pharmacology and neurobehavioral studies
In order to understand complex behaviors observed in nature, scientists have always tried
to develop models that could be used and tested under controlled conditions in the labora‐
tory. In the last 30 years a new animal model, zebrafish (Danio rerio), has emerged as a pow‐
erful tool mostly for studying developmental biology. The scientific potential of zebrafish
was originally assessed by George Streisinger (Streisinger et al., 1981). This work was the
starting point for rapid progress in molecular and genetic analysis of zebrafish neurodevel‐
opment, which allowed the construction of many genetic mutants and the identification of
several genes that affect different brain functions such as learning and memory (Norton &
Bally-Cuif, 2010). During the last decade zebrafish has also become an attractive model for
behavioral and drug discovery studies, particularly those related to actions in the central
nervous systems (Chakraborty & Hsu, 2009; King, 2009; Rubinstein, 2006; Zon & Peterson,
2005).
Zebrafish develop rapidly and almost all organs are developed at 7 days post-fertilization.
Their fecundity makes it easy to obtain large numbers of individuals for experimentation,
which are relatively inexpensive to maintain. In addition, they can absorb chemical substan‐
ces from their tank water, and their genome has been almost fully sequenced, which makes
genetic manipulation more accessible. These characteristics have stimulated the use of ze‐
brafish in medicinal chemistry to assay the effects of different compounds in whole animals
(Goldsmith, 2004; Kaufman & White, 2009). Another attractive characteristic of zebrafish is
its potential for use in in vivo high-throughput screening assays. Consequently, a number of
studies which take advantage of this possibility have been reported recently (Kokel et al.,
2010; Kokel & Peterson, 2011; Rihel et al., 2010; Zon & Peterson, 2005).
Zebrafish exhibit many social characteristics that can be assimilated to those observed in
mammals. They recognize each other by sight and odor (Tebbich et al., 2002) and display an
interesting social learning (Reader et al., 2003). This teleost also shows a characteristic ag‐
gressive behavior (Payne, 1998), a pheromone-mediated danger alarm (Suboski, 1988; Sub‐
oski et al., 1990), cognitive and adaptive behaviors such as habituation (Miklosi et al., 1997;
Miklosi & Andrew 1999), spatial navigation abilities and Pavlovian conditioning (Hollis,
1999). These features make this species a valuable tool for either the development or the
adaptation of behavioral paradigms. Thus, behavioral protocols such as an aquatic version
of the T-maze, which is used for studies of discrimination, reinforcement and memory in ro‐
dents, had been used to assess color discrimination in zebrafish (Colwill et al., 2005). Anoth‐
er interesting model is the aquatic version of conditioned place preference (CPP), where the
fish can be exposed to different stimuli in two separate compartments and is then allowed to
freely explore the apparatus without partition (Darland & Dowling, 2001). A further para‐
digm, the novel tank diving test, has been used by different research groups (Bencan & Lev‐
in 2008; Bencan et al., 2009; Egan et al., 2009; Levin et al., 2007) as a model for anxiety. It is
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conceptually similar to the rodent open field test, because it takes advantage of the instinc‐
tive behavior of both zebrafish and rats to seek refuge when exposed to an unfamiliar envi‐
ronment (Levin et al., 2007). In the case of the novel tank diving test, the fish dives to the
bottom of the tank and remains there until it presumably feels safe enough to explore the
rest of the tank and gradually starts to explore the upper zone (Egan et al., 2009). Similar
observations can be made in an open field test for rodents, where initially they spend a lot of
time near the walls, which is considered as an indication of an anxious state. The time spent
by the zebrafish in the lower or upper part of the tank, as well as erratic movements, have
been established as anxiety indices (Egan et al., 2009). It is considered that the zebrafish is
anxious when it shows a longer latency to enter the upper part of the tank, or when the time
spent at the top is reduced. Conversely, when an anxiolytic drug is administered, animals
spend much more time in the upper portion of the tank. Figure 1 illustrates this response by
showing the typical traces of motor activity observed for control animals (left) and for ani‐
mals exposed to nicotine (right), which has been reported to have anxiolytic properties in
this paradigm (Levin et al., 2007).
Based on these findings, the potential of zebrafish for neurobehavioral studies is increasing‐
ly recognized (Bencan & Levin, 2008; Eddins et al., 2010). Thus, this animal has been used as
a model in studies of memory (Levin & Chen, 2006), anxiety (Bencan et al., 2009; Levin et al.,
2007), reinforcement properties of drugs of abuse (Ninkovic & Bally-Cuif, 2006), neuropro‐
tection of dopaminergic neurons (McKinley et al., 2005), and movement disorders (Flinn et
al., 2008).
Figure 1. Representative traces of characteristic behavior of control-saline- (left) and nicotine- (right) treated zebra
fish. Traces were recorded during 5 min in a glass trapezoidal test tank (22.9 cm long at the bottom, 27.9 cm long at
the top, 15.2 cm high, 6.4 cm wide), filled with 1.5 L of artificial sea water. Nicotine was administered 5 min before the
test. All other experimental conditions were as previously published (Levin et al., 2007).
A final word of caution should be said regarding the apparent usefulness of zebrafish as a
research tool. One critical aspect to be considered when using animal models to understand
a specific behavior is its validity. Mammals such as rats and mice have been widely used as
models to study several functions since, among other characteristics, many brain regions
and their neurotransmitter systems are well characterized. Thus, even though genome and
the genetic pathways controlling signal transduction and development appear to be highly
conserved between zebrafish and humans (Postlethwait et al., 2000), further validation of
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this model is needed, particularly if human systems or conditions are the final aims to be
addressed.
2.1.1. Monoamine oxidase: general characteristics and the impact of crystal structures on the
understanding of enzyme function and inhibition
Monoamine oxidase (monoamine oxygen oxidoreductase (deaminating) (flavin-containing);
EC 1.4.3.4; MAO) is a key enzyme in the inactivation of neurotransmitters such as serotonin,
dopamine and noradrenaline. In mammals it exists in two isoforms termed MAO-A and
MAO-B which have molecular weights of ~60 kDa. Both proteins are outer mitochondrial
membrane-bound flavoproteins, with the FAD cofactor covalently bound to the enzyme.
MAO-A and MAO-B are encoded by separate genes (Kochersperger et al., 1986; Lan et al.,
1989) and the isoforms from the same species show about 70% sequence identity, whereas
85-88% identity is observed between the same isoforms from human and rat (Nagatsu,
2004). Both neurological and psychiatric diseases have been related to MAO dysfunction.
Consequently, the search for inhibitors of each isoform has lasted decades. Currently, selec‐
tive inhibitors of MAO-A are used clinically as antidepressants and anxiolytics, while MAO-
B inhibitors are used to reduce the progression of Parkinson’s disease and of symptoms
associated with Alzheimer’s disease (Youdim et al., 2006).
In 2002, Binda and colleagues (Binda et al., 2002) published a groundbreaking article show‐
ing the high-resolution structure of human MAO-B in complex with the irreversible inhibi‐
tor pargyline. Subsequent structures of this enzyme (Binda et al., 2003, 2004), as well as that
of rat MAO-A (Ma et al., 2004), and more recently human MAO-A (De Colibus et al., 2005;
Son et al., 2008), have allowed a detailed comparison of the overall structures of both iso‐
forms, and new insights regarding their active sites (Edmondson et al., 2007, 2009; Reyes-
Parada et al., 2005). Based on these findings, the substrate/inhibitor binding site of both
isozymes can be described as a pocket lined by the isoalloxazine ring of the flavin cofactor
and several aliphatic and aromatic residues (in the second part, close ups of this binding site
are depicted in Figures 5 and 8). In particular, two conserved tyrosine residues (Y407, Y444
and Y398, Y435 in MAO-A and -B, respectively), whose aromatic rings face each other, are
located almost perpendicularly to the isoalloxazine ring defining an “aromatic cage”. This
conformational arrangement provides a path to guide the substrate amine towards the reac‐
tive positions on the flavin ring and therefore seems to be essential for catalytic activity. In
addition, a critical role of residues G215 and I180 of MAO-A (G206 and L171 being the corre‐
sponding residues in MAO-B) in the orientation and stabilization of the substrate/inhibitor
binding can be inferred from the X-ray diffraction data. In MAO-B, the substrate/inhibitor
binding site is a cavity (~400 Å3, termed the “substrate cavity”) which can be distinguished,
in some cases, from another hydrophobic pocket (~300 Å3, termed the “entrance cavity”) lo‐
cated closer to the protein surface. It has been demonstrated that the I199 side-chain can act
as a “gate” opening or closing the connection between the two cavities by modifying its con‐
formation (Binda et al., 2003). In contrast, the MAO-A binding site consists of a single cavity
(De Colibus et al., 2005; Ma et al., 2004). It should be noted that, although residues lining the
binding site of human and rat MAO-A are identical, the human MAO-A cavity is larger
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(~550 Å3) than that in rat MAO-A (~450 Å3). Remarkably, an exchanged location of aromatic
and aliphatic nonconserved residues in the active sites of MAO-A and MAO-B (F208/I199
and I335/Y326, respectively) has been implicated in the affinity and selective recognition of
substrates and inhibitors, and provides a molecular basis for the development of specific re‐
versible inhibitors of each isoform (Edmondson et al., 2009).
The availability of the aforementioned crystal structures has made an enormous impact on
our knowledge about the function and regulation of the enzyme and has also allowed a
quicker pace in the rational design of novel MAO inhibitors. Different theoretical ap‐
proaches and computational methods have been used since, to explore how, where and
why some interactions are central in MAO-ligand complexes. For instance, quantum me‐
chanics calculations have been used to obtain insights about the mechanism by which
amines are oxidized by MAO (Erdem & Büyükmenekşe, 2011), whereas molecular dynamics
simulations have been recently employed to study specific interactions involved in the ac‐
cess of reversible MAO inhibitors to their binding site (Allen & Bevan 2011). In addition, a
number of studies describing potent and selective inhibitors have been reported during the
last decade and in most of them molecular simulation approaches have been used to ration‐
alize and/or to predict the functional interactions between the proteins and their inhibitors.
Figure 2 illustrates this situation by showing the progression of published articles about
MAO in which computational methodologies were used.
It should be pointed out however, that crystal structures only provide a snapshot of one of
the many conformations available to proteins. Therefore theoretical (and experimental) ap‐
proaches, adequately considering dynamic aspects, will grow in importance in order to bet‐
ter understand the physiological functioning of these enzymes.
Figure 2. Progression of research articles involving docking studies on MAO before and after (2002) the first three-
dimensional structure of MAO was deposited in the Protein Data Bank. Data from PubMed. “MAO” and “docking”
were used as keywords.
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2.1.2. Comparative functional and structural information about zebrafish MAO and its mammalian
counterparts
Unlike mammals, zebrafish have only one MAO gene (Anichtchik et al., 2006; Setini et al.,
2005). This gene is located in chromosome 9 and exhibits an identical intron-exon organiza‐
tion as compared to mammals, which suggests a common ancestral gene (Anichtchik et al.,
2006; Panula et al., 2010). Sequencing studies have shown that zebrafish MAO (zMAO) con‐
tains 522 amino acids and has a molecular weight of about 59 kDa (Setini et al., 2005), which
is very similar to that found in mammalian MAO-A and MAO-B. zMAO displays about 70%
identity with human MAO-A or -B, and its predicted secondary structure indicates that the
flavin-binding-, the substrate- and the membrane-binding- domains, which are typical in
other MAOs, should also be present in the fish enzyme. Indeed, a recent study (Arslan &
Edmondson, 2010) has demonstrated that (like the mammalian isoforms), zMAO is also a
mitochondrial enzyme, presumably bound to the outer membrane, and that the flavin cofac‐
tor is covalently bound to the protein via an 8α-thioether linkage likely established with
C406. Beyond its overall identity, the amino acid sequence of the presumed zMAO binding
domain shows ~67% and ~83% identity with the corresponding binding sites of human
MAO-B and MAO-A respectively (Panula et al., 2010). Interestingly, some residues that
have been shown to be critical for inhibitor and substrate selectivity in human MAOs such
as the pairs F208/I335 (in MAO-A) and I199/Y326 (in MAO-B), are identical or conservative‐
ly replaced in zMAO (F200/L327) as compared with MAO-A.
Regarding functional studies, recent data obtained using para-substituted benzylamine ana‐
logs as substrates suggest that, as in mammalian MAOs, α-C-H bond cleavage is the rate-
limiting step in zMAO catalysis (Aldeco et al., 2011). Furthermore, a variety of substrates
and inhibitors have been tested against zMAO. Preferential substrates of both MAO-A (e.g.
serotonin) and MAO-B (e.g. phenethylamine, benzylamine, MPTP) as well as non-selective
substrates such as tyramine, dopamine or kynuramine, have been shown to be deaminated,
although with different catalytic efficiency, by zMAO (Aldeco et al., 2011; Anichtchik et al.,
2006; Arslan & Edmondson, 2010; Sallinen et al., 2009; Setini et al., 2005). In addition, irre‐
versible selective inhibitors such as clorgyline (MAO-A) or deprenyl (MAO-B) exhibit simi‐
lar inhibitory profiles toward zMAO (Anichtchik et al., 2006; Arslan & Edmondson, 2010;
Setini et al., 2005). Interestingly, the in vivo administration of deprenyl to zebrafish increases
serotonin levels about 10-fold while levels of dopamine remain unchanged (Sallinen et al.,
2009). These data indicate that zMAO is essential for serotonin metabolism in zebrafish, but
also underline the distinctive character of this enzyme since in rodents dopamine concentra‐
tions are increased after deprenyl treatment, whereas serotonin levels remain unchanged.
Structurally diverse reversible MAO inhibitors such as harmane, tetrindole, methylene blue,
amphetamine, 8-(3-chlorostyryl)-caffeine, 1,4-diphenyl-1,3-butadiene, farnesol, safinamide
or zonisamide display a wide range of inhibitory potencies, from nM to µM to no effect,
against zMAO (Aldeco et al., 2011; Binda et al., 2011). Remarkably, methylene blue is the
most potent zMAO inhibitor tested thus far, exhibiting a Ki value of 4 nM.
Based on sequence similarity, substrate preference and inhibitor sensitivity, it has been con‐
sistently suggested that the functional properties of zMAO resemble more strongly those of
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MAO-A than those of MAO-B. Nevertheless, virtually all articles published so far recognize
that, although some overlapping properties can be detected, zMAO also shows characteris‐
tics of its own that distinguish it from its mammalian counterparts.
2.2. Recent developments in computational methods to evaluate similarities between
ligand-binding sites
The concept of protein binding-site similarity and the development of methods to evaluate it
are receiving much attention. This is viewed as a step forward in protein classification, as
compared with classical sequence-based approaches, since it should allow proteins with low
sequence similarity but high similarity at their binding sites to be related (Milletti & Vulpet‐
ti, 2010). On the contrary, as will be analyzed below, this approach can also detect subtle dif‐
ferences between highly homologous proteins, and therefore be useful to determine the
suitability of non-human proteins as models for drug design aimed to the treatment of hu‐
man conditions.
One of the newest applications of the study of binding site similarities is polypharmacology.
Thus, the classical idea that selective drugs acting on a single target related to one disease
will have maximal efficacy has been challenged by increasing evidence showing that most
clinically effective drugs bind to several targets, even if these targets are not originally relat‐
ed to the disease (Keiser et al., 2009; Schrattenholz & Soskić 2008). Even though this pharma‐
cological promiscuity may be seen as a negative property, primarily related with the
incidence of side effects, recent observations increasingly indicate that multitarget com‐
pounds might have better profiles regarding both efficacy and side effects, since they would
be acting on a pharmacological network, where several nodes underlie the physiopathology
of the disease (Apsel et al., 2008; Hopkins 2008). Thus, the concept of polypharmacology has
motivated several groups to find new drug-target associations, based on the idea that a giv‐
en compound can interact simultaneously with two or more relevant targets if they have
similar binding sites. It should be stressed that these associations are pursued considering
that two proteins could share a ligand even if they are structurally or functionally very dif‐
ferent (Kahraman et al., 2007).
One aspect that has critically fueled this field is the increasing availability of 3D protein
structures in public databases (almost 75.000), which allows us to explore the complexity of
protein-ligand interactions. This exploration has yielded important insights in order to ob‐
tain a good characterization of the binding sites and has confirmed the notion that protein-
ligand binding depends not only on shape complementarity but also on complementary
physicochemical features (Henrich et al., 2010).
Several algorithms have been developed to compare binding sites of different proteins. In
most of them, two main steps are present: the creation of a database that requires the calcu‐
lation of fingerprints describing each binding site and a pocket screening that requires mul‐
tiple similarity alignments between the query pocket and the database. These applications
are used as a strategy to assess specific issues, such as off-target identification for drug re-
purposing (Cleves & Jain, 2006; Keiser et al., 2009; Moriaud et al., 2011), functional classifica‐
tion of unknown proteins (Kinnings & Jackson, 2009; Russell et al., 1998), drug discovery by
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sequence analysis (Xie et al., 2009), detection of evolutionary relationships (Xie & Bourne,
2008) and polypharmacology predictions (Milleti & Vulpetti, 2010; Pérez-Nueno & Ritchie,
2011). The main step before finding similarity between two or more binding sites is their
characterization. Several methodologies have been proposed with this purpose: geometrics
approaches, which mainly analyze cavities through the exploration of the solvent-accessible
protein surface (Weisel et al., 2007); energetics approaches, which use van der Waals and
electrostatic energies to define cavities (Laurie & Jackson, 2005); structure and sequence
comparison approaches, which use the information of known binding sites to compare and
define unknown cavities through the analysis of sequence and structural similarity (Brylin‐
ski & Skolnick, 2009); and approaches involving the dynamics of protein structures, which
use dynamics simulations to include the natural flexibility of proteins and possible allosteric
modifications of binding sites (Landon et al., 2008). Although the determination of similari‐
ties between binding sites could seem a simple mathematical method, several approaches
have been developed using different characteristics. For example, the Isocleft algorithm
measures the similarity by initially defining a cleft in any protein to be compared. These
clefts are determined by a set of overlapping spheres that are represented by the van der
Waals radii of atoms in the binding sites. Finally each cleft is viewed like a graph and the
similarity is measured by finding the largest common subgraph (Najmanovich et al., 2008).
The SitesBase algorithm uses a triangular geometric determination of binding sites establish‐
ing the cutoff at 5 Å. Similarity is measured by an atom–atom score which finds the largest
possible matching constellation (similar atom types with a similar spatial orientation) (Gold
& Jackson, 2006). The ProFunc server uses sequence and structural information to find simi‐
larities between binding sites. This process includes a phylogenetic component that is used
for the identification of homologous proteins (Laskowski et al., 2005). The Sumo algorithm
flags each functional group as a node in a graph. Then the similarity is measured through a
strategy that does not necessarily find the maximal common subgraph between a pair of
binding sites (Jambon et al., 2003). The FLAP algorithm utilizes GRID methodology to calcu‐
late the energy of interaction between a molecular probe and the binding sites. These inter‐
actions, which include van der Waals and electrostatic terms, are then compared through a
geometric approach (Baroni et al., 2007). In another recently developed algorithm (Hoff‐
mann et al., 2010) the binding sites are represented as a set of atoms in the 3D space descri‐
bed by 3D vectors. Initially the algorithm calculates the similarity between two binding sites
comparing vectors that only consider the atom coordinates, although different additional
parameters such as atom type and charges could be included in the algorithm. The Pocket‐
Match algorithm involves three basic steps: a) each binding site is represented as a sort list
of distances between three selected points in every amino acid present at one specific dis‐
tance from the ligand, b) the two sets of sorted distances are aligned and c) finally the simi‐
larity percentage is calculated (Yeturu & Chandra, 2008).
Although most algorithms used to measure the similarities between binding sites have
shown high performance when the comparison involves related proteins, doubtful results
are obtained when the proteins are not related. In these cases it is very important to select
the best algorithm taking into account some critical issues: a ligand may change its orienta‐
tion in different binding sites; some protein-ligand conformations may have a favorable
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binding energy, but natural allosteric regulations (not always considered) might not favor
such conformations; protein structures from databases could have been determined in dif‐
ferent conformational states (active, inactive, closed, open, etc.); finally, it is also very impor‐
tant to consider the solvent and ion concentrations in every system.
Beyond these considerations, the continuous increase in both the number of protein struc‐
tures and computational power, augurs the development of ever more accurate similarity
searching tools, which likely will allow not only better results in virtual screening programs
but also a novel view on the evolution of structure and function of proteins.
3. MAO from different species: a biochemical evaluation and a theoretical
analysis using molecular simulation and a biostatistical algorithm
As mentioned, even though amino acids lining the zMAO binding site exhibit a high level of
identity with those of rat and human MAOs, a few studies have shown that the fish’s en‐
zyme shows unexpected sensitivities for known specific substrates and inhibitors. Since ze‐
brafish has been proposed as a model that could be useful for the identification of novel
MAO inhibitors (Kokel et al., 2010), we further characterized zMAO using three different
approaches. First, we determined the inhibitory potency of a small series of compounds
which have been previously evaluated against rat and human MAOs. Then, we built homol‐
ogy models of zMAO based on the crystal structures of human MAO-A or MAO-B and per‐
formed docking experiments with a drug selected from the biochemical evaluations. Finally,
we used the recently described algorithm PocketMatch (Yeturu & Chandra, 2008) to explore
similarities and differences between MAO isoforms from human, rat and zebrafish.
3.1. Biochemical evaluation
3.1.1. Methods
4-Methylthioamphetamine (MTA), 2-naphthylisopropylamine (NIPA), (6-methoxy-2-naph‐
thy)lisopropylamine (MeONIPA), all as hydrochloride salts, 2-(4’-butoxyphenyl)thiomor‐
pholine (BTI), 2-(4’-benzyloxyphenyl)thiomorpholine (ZTI), both as oxalate salts, as well as
2-(4’-butoxyphenyl)thiomorpholin-5-one (BTO) and 2-(4’-benzyloxyphenyl)thiomorpho‐
lin-5-one (ZTO) were synthesised following published methods (Hurtado-Guzmán et al.,
2003; Lühr et al., 2010; Vilches-Herrera et al., 2009). The expression and purification of
zMAO in Pichia pastoris was performed as previously described (Arslan & Edmondson,
2010). Enzyme kinetic studies were done spectrophotometrically in 50 mM potassium phos‐
phate buffer (pH = 7.4), 0.5% (w/v) reduced Triton X-100 with kynuramine as substrate. The
spectrophotometer used was a Perkin-Elmer Lambda-2 UV–Vis at 25 °C.
3.1.2. Results and discussion
Figure 3 shows the chemical structures of the inhibitors evaluated.
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Figure 3. Chemical structures of the compounds used in the biochemical evaluation
Table 1 summarizes the effects of these compounds upon zMAO and also includes, for com‐
parative purposes, the reported values of their inhibitory activities against MAO-A and -B
from human and rat (Fierro et al., 2007; Hurtado-Guzmán et al., 2003; Lühr et al., 2010;
Vilches-Herrera et al., 2009).
Compound
Ki (µM)
zMAO hMAO-A rMAO-A hMAO-B rMAO-B
MTA a NE 0.13 ± 0.02 0.25 ± 0.02 NE NE
NIPAb 17.7 ± 2.6 0.48 ± 0.31 0.42 ± 0.04 >100 >100
MeONIPAb 4.8 ± 0.4 0.24 ± 0.02 0.18 ± 0.05 5.1 ± 0.4 16.3 ± 7.8
BTOc NE 10.0 ± 0.3 50.9 ± 6.1 0.46 ± 0.18 0.16 ± 0.01
ZTOc NE >100 27.5 ± 4.6 0.048 ± 0.03 0.074 ± 0.003
BTIc 30.4 ± 3.8 2.5 ± 0.2 14.1 ± 1.2 0.068 ± 0.05 0.27 ± 0.02
ZTIc NE >100 19.0 ± 0.4 0.038 ± 0.003 0.13 ±0.01
Table 1. zMAO inhibitory properties of known selective mammalian MAO inhibitors. Comparative data for human
and rat MAO inhibition are from: aHurtado-Guzmán et al., 2003; bVilches-Herrera et al 2009; cLühr et al, 2010. NE: No
effect
The amphetamine derivative MTA, which is a potent and selective inhibitor of rat and hu‐
man MAO-A (Fierro et al., 2007; Hurtado-Guzmán et al., 2003), showed no significant effect
upon zMAO activity. Similarly, the 2-arylthiomorpholine analogue ZTI, and the 2-arylthio‐
morpholin-5-one derivatives BTO and ZTO, which are highly selective MAO-B inhibitors
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(Lühr et al., 2010), did not inhibit the fish’s enzyme. In contrast, naphthylisopropylamine de‐
rivatives NIPA and MeONIPA, which are selective inhibitors of MAO-A (Vilches-Herrera et
al., 2009), as well as the 2-arylthiomorpholine derivative BTI which selectively inhibits
MAO-B (Lühr et al., 2010), exhibited zMAO inhibitory properties with Ki values in the mi‐
cromolar range. MeONIPA was the most potent compound of the series evaluated, showing
a Ki value (4.8 µM) very similar to that found against human MAO-B (5.1 µM). These results
agree with a notion that can be inferred from previous data (Aldeco et al., 2011; Anichtchik
et al., 2006), indicating that effects on zMAO cannot be straightforwardly used to predict an
effect upon either MAO-A or MAO-B. In addition, these data suggest that the zMAO bind‐
ing site is significantly different from those of both MAO-A and MAO-B from mammals.
3.2. Homology models of zMAO and molecular docking
3.2.1. Modeling methods
Since neither the MAO-A nor MAO-B structure can be chosen a priori as a better template for
modeling zMAO, we decided to build two different models using each isoform of human
MAO as templates. The MAO-A (Protein Data Bank, PDB code: 2BXS) and MAO-B (PDB
code: 2BYB) crystal structures at 3.15 Å and 2.2 Å resolution respectively (De Colibus et al.,
2005) were employed. The amino acid sequence and crystal structure of each protein were
extracted from the National Center for Biotechnology Information (NCBI) and PDB databas‐
es. Sequence alignments were prepared separately. Models were built using standard pa‐
rameters and the outcomes were ranked on the basis of the internal scoring function of the
program MODELLER9v6 (Sali & Blundell, 1993). The best model obtained in each case (us‐
ing MAO-A or MAO-B as template) was submitted to the H++ server (Gordon et al., 2005;
http://biophysics.cs.vt.edu/H++) to compute pKa values of ionizable groups and to add miss‐
ing hydrogen atoms according to the specified pH of the environment. Each structure select‐
ed was inserted into a POPC membrane, TIP3 solvated and ions were added creating an
overall neutral system simulating approximately 0.2 M NaCl. The ions were equally distrib‐
uted in a water box. The final system was subjected to a molecular dynamics (MD) simula‐
tion for 5 ns using NAMD 2.6 (Phillips et al., 2005). The NPT ensemble was used to perform
MD calculations. Periodic boundary conditions were applied to the system in the three coor‐
dinate directions. A pressure of 1 atm was used and temperature was kept at 310 K. The
simulation time was sufficient to obtain an equilibrated system (RMSD < 2 Å). Stereochemi‐
cal and energy quality of the homology models were evaluated using the PROSAII server
(Wiederstain & Sippl 2007) and Procheck (Laskowski et al., 1993)
3.2.2. Docking methods
Dockings of (S)-MeONIPA in the zMAO models, as well as in the human MAO-A and
MAO-B structures were done using the AutoDock 4.0 suite (Morris et al., 1998). MeONIPA
was selected for this study since it was the most potent zMAO inhibitor of the series evaluat‐
ed and because it also inhibited both human MAO-A and MAO-B at low concentrations.
The choice of the (S)-isomer for MeONIPA docking experiments was done on the basis that
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(S)-amphetamine derivatives (which are always dextrorotatory) are usually the eutomers at
MAO (Hurtado-Guzmán et al., 2003). All other docking conditions were as previously re‐
ported (Fierro et al., 2007; Vilches-Herrera et al., 2009). Briefly, the grid maps were calculat‐
ed using the autogrid4 option and were centered on the putative ligand-binding site. The
volumes chosen for the grid maps were made up of 40 × 40 × 40 points, with a grid-point
spacing of 0.375 Å. The autotors option was used to define the rotating bond in the ligand.
The docked compound complexes were built using the lowest docked-energy binding posi‐
tions. MeONIPA was built using Gaussian03 (Frisch et al., 2004) and the partial charges
were corrected using ESP methodology.
3.2.3. Results and discussion
Figure 4 depicts the global zMAO models obtained using human MAO-A (left) and human
MAO-B (right) as templates. As expected, the overall structure of zMAO was similar to
those of the human enzymes. The presumed ligand binding site appears lined by a series of
hydrophobic residues and the isoalloxazine ring of the flavin cofactor (top inset Fig. 4). Ami‐
no acids forming the binding site of zMAO and human MAO-A and -B are shown in insets
of Figure 4.
Figure 4. Cartoons of zMAO models obtained using human MAO-A (left) or human MAO-B (right). Insets show the
main amino acids of the active sites of zMAO (top), human MAO-A (left) and human MAO-B (right). Amino acids in
white, green or blue indicate apolar, polar or positively charged residues respectively.
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As shown in Figure 5, docking experiments revealed that in both zMAO models, MeONIPA
exhibits a binding mode where the aromatic ring is oriented almost perpendicularly to the
isoalloxazine ring of FAD, with the methoxyl group pointing to the binding site entrance,
whereas the aminopropyl chain points toward the isoalloxazine ring and appears positioned
close to two tyrosine residues which, together with the isoalloxazine ring, form the so-called
aromatic cage (Figs. 5 A and 5B). Interestingly, docking of MeONIPA in both human MAO-
A and MAO-B, yielded binding modes where the inhibitor molecule adopted an almost op‐
posite orientation to those observed in zMAO models. Thus, the most energetically
favorable conformations of MeONIPA were those in which the amino group points away
from the flavin ring, whereas the methoxyl group is located between the corresponding ty‐
rosine residues (Figs. 5 C and 5D). These results suggest that the different inhibitory poten‐
cies of MeONIPA (and likely other inhibitors) toward zebrafish and human MAOs, might be
attributed to the differential binding modes exhibited by the drug. Similar conclusions at‐
tempting to explain why MAO inhibitors show differential inhibition properties upon MAO
from different species have been reached in previous studies (Fierro et al., 2007; Nandinga‐
ma et al., 2002). Moreover, our findings suggest that, even in the cases where similar poten‐
cies are detected, the mechanism of enzyme inhibition for a given drug might be different in
zebrafish and human MAOs.
Figure 5. Comparison of the binding modes of MeONIPA into zMAO (A and B), human MAO-A (C) and human MAO-B
(D) active sites. Figures 5 A and 5Bshow the docking poses of MeONIPA into zMAO models obtained using human
MAO-A and human MAO-B respectively. Main active site amino acid residues and FAD are rendered as stick models.
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3.3. Similarities between the binding sites of MAO from different species.
3.3.1. Protein structures employed
The structures of human and rat MAO-A co-crystallized with clorgyline (PDB codes: 2BXS
and 1O5W respectively) and human MAO-B co-crystallized with l-deprenyl (PDB code:
2BYB) were employed. Furthermore, structures of zMAO models and human MAO-A and
MAO-B obtained after docking of MeONIPA (see previous section), were used in additional
comparisons.
3.3.2. Binding site comparison methods
The PocketMatch algorithm was selected for this study due to its relatively low computa‐
tional complexity and high performance. All aspects involved in binding site comparisons
followed the procedure published in the original article describing the algorithm (Yeturu &
Chandra, 2008). Briefly, each binding site was considered as that determined by the residues
for which one or more atoms surround either a crystallographic or a docked ligand at a giv‐
en distance (4 Å by default; in some cases distances from 3 Å to 10 Å from the ligand were
considered; see following section). Each residue was classified into one of 5 groups, taken
into account its chemical properties. Then, each residue was represented as a set of three
points corresponding to the coordinates of the C-Alpha, the C-Beta and the Centroid Atom
of the side chain. Distances between every three points of each residue in the binding sites
were measured. All distances computed were sorted in ascending order and stored in sets of
distances organized by type of pairs of points and type of pairs of tags. The sorted and or‐
ganized distances were aligned and compared using a threshold of 0.5 Å, which was estab‐
lished considering the natural dynamics of biological systems. The similarity between sites,
referred to as the PMScore, was measured by scoring the alignment of the pair of sites under
comparison. Thus, the PMScore represents the percentage of the number of “matches” cal‐
culated over the maximal number of distances computed for each binding site. A PMScore
of 0.5 (50 %) or higher was considered as indicative of similarity between binding sites.
3.3.3. Results and discussion
Initially, we compared human and rat MAO-A. The amino acid sequence in the active sites
of both proteins is identical, and therefore we expected to find a high degree of similarity.
Surprisingly, a PMScore value of 0.27 was obtained after comparing the residues located at 4
Å from the ligand (clorgyline in both proteins), which is the PocketMatch default condition.
It should be considered that PMScores > 0.5 are indicative of binding site similarity, whereas
values below 0.5 indicate lack of similarity. It should also be noted that, as shown in the
original report by Yeturu & Chandra (2008), a distance of 4 Å from the ligand was clearly
suitable to find similarities between a series of structurally related and unrelated proteins.
Therefore, it was rather intriguing that such a low PMScore should be obtained, suggesting
the existence of relevant differences between rat and human MAO-A binding sites, most
likely in the form in which residues in close proximity to the ligand are arranged. Such a
conformational difference has been revealed by the crystal structures of both proteins,
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which show that the cavity-shaping loop 210–216 and specifically residues Gln215 and
Glu216 are differentially oriented in human and rat MAO-A (De Colibus et al., 2005). This
differential arrangement determines a larger volume of the active site of human MAO-A
(550 Å3) as compared to that of rat MAO-A (450 Å3). Thus, our results confirm that rat and
human MAOs are not as similar as could be inferred from the analysis of their amino acid
sequences, and highlight the sensitivity of PocketMatch to determine subtle differences be‐
tween highly related proteins.
Despite these considerations, we developed a script that allows the automatic evaluation of
PMScores considering distances from 3 Å to 10 Å from the ligand, with the hope that such
an analysis could yield further information regarding the similarity of the binding sites of
MAOs. Thus, we were able to build “similarity profiles”, which graphically show at what
distance from the ligand (if any) the binding sites begin to be similar. Figure 6 shows the
similarity profile after comparing rat and human MAO-A.
Figure 6. Similarity profile between rat and human MAO-A, both co-crystalized with clorgyline, as calculated using
PocketMatch. The horizontal black line indicates PMScore = 0.5. The vertical black line indicates the distance from the
ligand where the PMScore begins to be consistently greater than 0.5. Each point corresponds to the PMScore.
As can be seen, PMScores greater than 0.5 appeared at 4.5 Å and were consistently observed
at longer distances from the ligand. Since most amino acids located at 4.5 Å from the ligand
line the binding site (see Figure 8A and 8B), these results indicate that, beyond the shape dif‐
ferences revealed by crystal structures and detected by PocketMatch, the binding sites of
MAO-A from rat and human are quite similar.
In contrast, when binding sites of human MAO-A and MAO-B were compared, PMScores
indicating similarity (> 0.5) were only found at distances higher than 6.4 Å from the ligand
(Fig. 7).
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Figure 7. Similarity profile between human MAO-A (co-crystalized with clorgyline) and human MAO-B (co-crystalized
with deprenyl), as calculated using PocketMatch. The horizontal black line indicates PMScore = 0.5. The vertical black
line indicates the distance from the ligand where the PMScore begins to be consistently greater than 0.5. Each point
corresponds to the PMScore.
As shown in Figures 8C and 8D, at a distance of 6.4 Å from the ligand, several amino acids
considered in the similarity determination are located outside the binding site.
Figure 8. Binding site residues surrounding the inhibitors clorgyline (blue) and deprenyl (pink) bound to human MAO-
A (HMAO-A), rat MAO-A (RMAO-A) or human MAO-B (HMAO-B). Figures 8A and 8B show the residues located at 4.5
Å from the ligand, while figures 8C and 8D show the residues located at 6.5 Å from the ligand
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Therefore, the similarity profile shown in Figure 7 indicates that human MAO-A and MAO-
B binding sites are less similar than those of rat and human MAO-A. It also shows that, al‐
though showing differences at their binding sites, human MAO-A and MAO-B exhibit a
high degree of global structural similarity (all PMScores obtained at distances longer than
6.5 Å were well over 0.5). Though both findings might be considered obvious from the anal‐
ysis of each protein sequence and function, they confirm the suitability of PocketMatch to
find and predict such characteristics, an aspect that could be particularly useful when com‐
paring proteins from which less functional information is available. In addition, our results
suggest that in some cases the determination of similarity profiles can be more informative
than point comparisons.
Figures 9 and 10 show the similarity profiles after comparing the homology models of
zMAO with those of human MAO-A and MAO-B, respectively. As mentioned, in all cases,
MeONIPA docked in each MAO structure was used as ligand.
Figure 9. Similarity profile between zMAO (in this case the model corresponds to that based on human MAO-A) and
human MAO-A, as calculated using PocketMatch. In both proteins, docked MeONIPA was used as ligand. The horizon‐
tal black line indicates PMScore = 0.5. The vertical black line indicates the distance from the ligand where the PMScore
begins to be consistently greater than 0.5. Each point corresponds to the PMScore.
As shown in Figures 9 and 10, PMScores indicative of similarity between the binding sites of
zMAO and human MAO-A or MAO-B (i.e., PMScore > 0.5) were consistently seen at distan‐
ces higher than 6 Å from the ligand. It should be noted that comparable values were ob‐
tained even though the zMAO model was built using either human MAO-A or MAO-B as
templates, and regardless of which human enzyme was used for the comparison. These re‐
sults suggest that the zMAO binding site is as different from those of both human isoforms
as the binding site of MAO-A differs from that of MAO-B. In addition, the similarity profiles
of zMAO against both human proteins indicate that global structural similarity is found
across these species, while the main differences are found at their binding sites. Since, to
perform the similarity determination, PocketMatch considers both the shape and the chemi‐
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cal nature of the residues forming the site (Yeturu & Chandra, 2008), these two factors are
likely involved in the differences detected between the MAO isoforms. Considering the se‐
quence identity between zebrafish and human enzymes, one may predict that conformation‐
al differences are more important when comparing zMAO and human MAO-A, while the
chemical features of the residues are more relevant to the differences between zMAO and
human MAO-B. Nevertheless, further analyses are necessary to determine the relative con‐
tribution of each aspect to the differences found.
4. Conclusion
In summary, results from biochemical evaluation, molecular simulation and similarity de‐
tection studies presented here add novel evidence to the notion that even though zMAO ex‐
hibits some functional and structural properties overlapping those of MAO-A and -B, the
zebrafish protein behaves quite distinctively from its mammalian counterparts. Therefore,
although still an attractive model for drug discovery, in our opinion zebrafish is not a useful
model for the identification of novel MAO inhibitors aimed for use in humans.
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